To investigate the effect of Cyclosporin A (CsA) on pancreatic β cell function, we performed retrospective and prospective studies in renal transplant recipients (n=10). In these patiens, CsA was administered at a dose of 6-8mg/kg/day after operation.
In the retrospective study, 4 renal transplant recipients who developed diabetes mellitus after operation were investigated (diabetic group), and it was revealed that the mean trough level of CsA was elevated to 248±97 ng/m
l.
In the prospective study, in which 6 patients were investigated, trough levels of CsA were frequently monitored in an attempt to maintain a level of 100 to 200 ng/m
l by changing the administered dose. Oral glucose tolerance test (75 g), intravenous glucose tolerance test (0.3 g/kg), and intravenous glucagon loading test (1 mg) were carried out before, and 2 weeks and 6 weeks after operation in each patient. Thee were no significant changes in glucose tolerance and endogenous insulin secretory capacity before and after operation, and no patients developed diabetes mellitus after operation (non-diabetic group). In this group, the mean trough level of CsA was maintained at 119±44 ng/m
l. There were no significant differences in prednisolone and CsA doses between the diabetic and non-diabetic groups.
This study suggested that CsA at a high serum concentration and with simultaneously administered corticosteroid might be toxic to pancreatic β cells. Thus, frequent monitoring of CsA levels might be beneficial in preventing this adverse effect of CsA on pancreatic β cells.
View full abstract